Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Ritonavir [USAN:USP:INN:BAN]
RN: 155213-67-5
UNII: O3J8G9O825
InChIKey: NCDNCNXCDXHOMX-XGKFQTDJSA-N

Note

  • An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.

Molecular Formula

  • C37-H48-N6-O5-S2

Molecular Weight

  • 720.9552
 

Classification Codes

  • Anti-HIV Agents
  • Anti-Infective Agents
  • Anti-Retroviral Agents
  • Antiretroviral
  • Antiviral
  • Antiviral (COVID-19)
  • Antiviral Agents
  • Cytochrome P-450 CYP3A Inhibitors
  • Cytochrome P-450 Enzyme Inhibitors
  • Enzyme Inhibitors
  • HIV Protease Inhibitors
  • Metabolic Side Effects of Drugs and Substances
  • Protease Inhibitor
  • Protease Inhibitors
  • Viral Protease Inhibitors

Names and Synonyms

Name of Substance

  • Ritonavir
  • Ritonavir [USAN:USP:INN:BAN]

MeSH Heading

  • Ritonavir

Synonyms

  • 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
  • 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
  • A-84538
  • Abbott 84538
  • Abbott-84538
  • ABT-538
  • DRG-0244
  • HSDB 7160
  • Norvir
  • NSC 693184
  • NSC 760369
  • Ritonavir
  • RTV
  • TMC 114r
  • UNII-O3J8G9O825

Systematic Name

  • 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S-(5R*,8R*,10R*,11R*))-

Mixture Name

  • Kaletra

Registry Numbers

CAS Registry Number

  • 155213-67-5

FDA UNII

  • O3J8G9O825

System Generated Number

  • 0155213675

Structure Descriptors

InChI

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

InChIKey

NCDNCNXCDXHOMX-XGKFQTDJSA-N

Smiles

CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)Cc4ccccc4

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD oral > 2500mg/kg (2500mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998.
mouse LDLo intravenous 65mg/kg (65mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998.
rat LD oral > 2500mg/kg (2500mg/kg) BEHAVIORAL: TREMOR

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998.
rat LDLo intravenous 35mg/kg (35mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998.